New results build on previously reported significant recurrence-free survival (rfs) benefit seen in these patients
KEYTRUDA is now approved as monotherapy for adults with Renal Cell Carcinoma (RCC)
First Positive Study for KEYTRUDA in Adjuvant Stage IB-IIIA NSCLC
Packaged junk food which is a major component of unhealthy diets is responsible for more deaths worldwide than any other risk factor
The medicine is now approved for eight indications across five different types of cancer in China.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
